HUTCHMED’s Post

In 2023, an estimated 297,790 new cases of invasive #breastcancer will be diagnosed in women in the U.S. as well as 55,720 new cases of non-invasive (in situ) breast cancer. Learn about risk factors and symptoms of breast cancer ➡️ https://bit.ly/3T22IE9 #BreastCancerAwareness

Do you have a mutation that increases your cancer risk? A family history of cancer? Screening for pancreatic cancer may be helpful for some. Read more in our review: https://ow.ly/8Fa750Qs9Ps #HelpNotHype #BehindtheCancerHeadlines #FacingOurRisk #hereditarycancer #pancreaticcancer

Early detection is crucial: Oral cancer is often treatable with high success rates when caught early. Don't let go of your smile. Enroll in the Free Oral Cancer Screening program. To know more about Screening, call 9881123006 #ABMH #AdityaBirlaMemorialHospital #Ummeed #oralcancer #cancercare #oralcancerscreening #freescreening

An excellent 👍 use case of RWE demonstrated by this interesting case study🧐 from NICE - National Institute for Health and Care Excellence. Key takeaway: 📝 Adherence to principles outlined in NICE’s real-world evidence framework 📃 Use of DataSAT tool (https://lnkd.in/gnPvGiSR) and RECORD-PE checklist (https://lnkd.in/gJ6G2_hu) to provide transparency in reporting 💡 Identifying key prognostic factors using targeted literature review and expert opinion ⚖️ Adjusting for the key prognostic factors using inverse probability of treatment weighting to address possible confounding #RWE #RWD #HTA #HealthtechnologyAssessment

NICE's real-world evidence framework is starting to have an impact. Read about how our best practice guidance shaped evidence for a recent appraisal of a cancer drug.

Colorectal cancer screening for average risk adults should start at 45, but if you have a family history of colorectal cancer you may need to get screened sooner and more often. Download our screening guide https://bit.ly/3v0mQ2W NEBRASKA CANCER COALITION #ColorectalCancerAwareness #FightBackNE

Today, Dr. Fabio Turco will be talking at the 3rd Optimal Cancer Care Alliance Virtual Meeting. His presentation on "EORTC 2238 “DeEscalate”, a pragmatic trial to revisit Intermittent Androgen Deprivation Therapy in the era of new AR pathway inhibitors" will take place at 10:00 PM CEST. For more information on Optimal Cancer Care: https://lnkd.in/ehyHZPey #CancerResearch #OptimalCancerCare #ClinicalTrials #Oncology #DeEscalate #TreatmentOptimisation #PragmaticTrials University of Chicago

Check out this article in TIME where our CSO of Oncology R&D Jeffrey Settleman delves into our legacy in precision medicine and vision for the future, where every person living with cancer has access to biomarker-driven treatment options that are right for their type of cancer. #PFEColleague

Check out this article in TIME where our CSO of Oncology R&D Jeffrey Settleman delves into our legacy in precision medicine and vision for the future, where every person living with cancer has access to biomarker-driven treatment options that are right for their type of cancer. #PFEColleague

Check out this article in TIME where our CSO of Oncology R&D Jeffrey Settleman delves into our legacy in precision medicine and vision for the future, where every person living with cancer has access to biomarker-driven treatment options that are right for their type of cancer. #PFEColleague